Helus Pharma Closes $50M Underwritten Offering

Key Facts

1Helus Pharma closed a US$50 million underwritten offering of 10,309,280 common shares at US$4.85 per share.

As clinical-stage pharmaceutical companies increasingly need cash to fund drug development, Helus Pharma closed a US$50 million underwritten offering. The offering consisted of 10,309,280 common shares at US$4.85 per share, according to a company press release.

The deal represents significant dilution for existing shareholders, adding over 10 million new shares to a company that remains pre-revenue and loss-making. Helus has not specified the use of proceeds, but the capital is expected to support ongoing research and development expenses.

HELP shares closed at $4.85 on June 23, 2026, exactly at the offering price, after trading between $4.75 and $5.05 during the session. No near-term catalysts appear on the calendar, leaving the focus on the company's ability to deliver clinical milestones that can justify its valuation.